Legal Representation
Attorney
Brian P. O'Donnell
USPTO Deadlines
Next Deadline
119 days remaining
NOA E-Mailed - SOU Required
Due Date
May 04, 2026
Extension Available
Until November 04, 2026
Application History
15 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 4, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 9, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 9, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 3, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 11, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 6, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 6, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 6, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 22, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 22, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 11, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 2, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 2, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 30, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Nucleic acid sequences for medical purposes; Pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions.
Additional Information
Design Mark
The mark consists of the wording "MYO" on top of the wording "TECHNOLOGY". The "O" in "MYO" consists of a helix with a line down the middle, inside of a circle and a second outer circle.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TECHNOLOGY"